Suppr超能文献

早期使用β受体阻滞剂是否能降低急性冠状动脉综合征患者的住院死亡率?

Does the early administration of beta-blockers improve the in-hospital mortality rate of patients admitted with acute coronary syndrome?

机构信息

Department of Emergency Medicine, State University of New York Downstate Medical Center, Brooklyn, NY, USA.

出版信息

Acad Emerg Med. 2010 Jan;17(1):1-10. doi: 10.1111/j.1553-2712.2009.00625.x.

Abstract

OBJECTIVES

Beta-blockade is currently recommended in the early management of patients with acute coronary syndromes (ACS). This was a systematic review of the medical literature to determine if early beta-blockade improves the outcome of patients with ACS.

METHODS

The authors searched the PubMed and EMBASE databases for randomized controlled trials from 1965 through May 2009 using a search strategy derived from the following PICO formulation of our clinical question: Patients included adults (18+ years) with an acute or suspected myocardial infarction (MI) within 24 hours of onset of chest pain. Intervention included intravenous or oral beta-blockers administered within 8 hours of presentation. The comparator included standard medical therapy with or without placebo versus early beta-blocker administration. The outcome was the risk of in-hospital death in the intervention groups versus the comparator groups. The methodologic quality of the studies was assessed. Qualitative methods were used to summarize the study results. In-hospital mortality rates were compared using a forest plot of relative risk (RR; 95% confidence interval [CI]) between beta-blockers and controls. Statistical analysis was done with Review Manager V5.0.

RESULTS

Eighteen articles (total N = 72,249) met the inclusion/exclusion criteria. For in-hospital mortality, RR = 0.95 (95% CI, 0.90-1.01). In the largest of these studies (n = 45,852), a significantly higher rate (p < 0.0001) of cardiogenic shock was observed in the beta-blocker (5.0%) versus control group (3.9%).

CONCLUSIONS

This systematic review failed to demonstrate a convincing in-hospital mortality benefit for using beta-blockers early in the course of patients with an acute or suspected MI.

摘要

目的

β受体阻滞剂目前被推荐用于急性冠状动脉综合征(ACS)患者的早期治疗。本研究系统回顾了医学文献,以确定早期使用β受体阻滞剂是否能改善 ACS 患者的预后。

方法

作者使用源自我们临床问题的以下 PICO 表述的搜索策略,在 1965 年至 2009 年 5 月期间在 PubMed 和 EMBASE 数据库中搜索随机对照试验:患者包括胸痛发作后 24 小时内发生急性或疑似心肌梗死(MI)的成年人(18 岁以上)。干预措施包括在出现症状后 8 小时内静脉或口服给予β受体阻滞剂。对照组包括标准药物治疗加或不加安慰剂与早期β受体阻滞剂治疗的比较。结局是干预组与对照组的住院期间死亡率。评估了研究的方法学质量。使用森林图汇总研究结果。使用相对风险(RR;95%置信区间[CI])比较β受体阻滞剂和对照组之间的住院死亡率。使用 Review Manager V5.0 进行统计分析。

结果

符合纳入/排除标准的有 18 篇文章(共 N = 72249 人)。对于住院死亡率,RR = 0.95(95% CI,0.90-1.01)。在这些研究中最大的一项(n = 45852)中,β受体阻滞剂组(5.0%)与对照组(3.9%)相比,观察到更高的(p < 0.0001)心源性休克发生率。

结论

本系统综述未能证明在急性或疑似 MI 患者病程早期使用β受体阻滞剂有令人信服的住院死亡率获益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验